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Gene targeting is the in situ manipulation of the sequence of an endogenous gene by the introduction of
homologous exogenous DNA. Presently, the rate of gene targeting is too low for it to be broadly used in
mammalian somatic cell genetics or to cure genetic diseases. Recently, it has been demonstrated that infection
with recombinant adeno-associated virus (rAAV) vectors can mediate gene targeting in somatic cells, but the
mechanism is unclear. This paper explores the balance between random integration and gene targeting with
rAAV. Both random integration and spontaneous gene targeting are dependent on the multiplicity of infection
(MOI) of rAAV. It has previously been shown that the introduction of a DNA double-stranded break (DSB) in
a target gene can stimulate gene targeting by several-thousand-fold in somatic cells. Creation of a DSB
stimulates the frequency of rAAV-mediated gene targeting by over 100-fold, suggesting that the mechanism of
rAAV-mediated gene targeting involves, at least in part, the repair of DSBs by homologous recombination.
Absolute gene targeting frequencies reach 0.8% with a dual vector system in which one rAAV vector provides
a gene targeting substrate and a second vector expresses the nuclease that creates a DSB in the target gene.
The frequencies of gene targeting that we achieved with relatively low MOIs suggest that combining rAAV
vectors with DSBs is a promising strategy to broaden the application of gene targeting.
Gene targeting is a process by which an exogenous gene
replaces an endogenous gene by homologous recombination. It
is used to create genetic change in murine embryonic stem cells
and in certain other specialized cell types, such as the chicken
B-cell line DT40 (5, 31). In general, however, the low sponta-
neous frequency of gene targeting has precluded its wide-
spread experimental use in mammalian somatic cell genetics.
In somatic cell lines, for example, gene targeting occurs at a
frequency of approximately one event per million transfected
cells (29). Moreover, while gene targeting would be a concep-
tually elegant way of performing gene therapy through gene
correction, the low spontaneous frequency has also precluded
its development for such an application. The regulation of
gene targeting is intimately related to the metabolism of exog-
enous DNA. In particular, the relative frequency of gene tar-
geting is directly related to the balance between the homolo-
gous and random integration of exogenous DNA and this
balance has important consequences for the type of genetic
change created. If, for example, exogenous DNA is integrated
by gene targeting via homologous recombination, then subtle
genomic changes can be created. If, on the other hand, exog-
enous DNA is integrated randomly, then insertional mutations
are created, a different type of genetic alteration. Understand-
ing whether cells passively or actively regulate the metabolism
of exogenous DNA, therefore, has important consequences in
understanding how genomes can be altered by the introduction
of foreign DNA. Moreover, understanding the underlying
mechanisms of gene targeting not only will give insight into
how cells regulate genomic alterations but could also lead to its
development as a tool for somatic cell genetics and gene ther-
apy.
The creation of a DNA double-stranded break (DSB) in the
target gene can increase the frequencies of both direct-repeat
recombination and gene targeting several-thousand-fold (4, 7,
9, 23, 28, 30, 32). When conditions are optimized for DSB-
mediated gene targeting, the frequency of gene targeting can
reach 3 to 5% (22). Thus, DSBs seem to be a central element
of the gene targeting mechanism. The powerful stimulatory
role of DSBs in gene targeting was found by transfecting cells
with naked DNA. For many cell types, however, transfection is
inefficient. It is important, therefore, to find an efficient deliv-
ery system for the gene targeting components (a DNA sub-
strate to direct the desired genetic change and a nuclease to
create a gene-specific DSB).
Viral vectors, and in particular, recombinant adeno-associ-
ated virus (rAAV), have broad cellular tropism and may be
preferred over transfection as a method for the delivery of
gene targeting components (20, 25). AAV vectors possess a
single-stranded DNA genome with inverted terminal repeats
that form hairpin structures at each end and can integrate
randomly by nonhomologous recombination (18, 26, 27, 34).
The ability of rAAV vectors to stably transduce cells has led to
their being used in human gene therapy trials for the treatment
of hemophilia (16). Russell and Hirata, however, showed that
rAAV could not only randomly integrate into the genome but
could also mediate gene targeting (24). They found that using
a multiplicity of infection (MOI) of 400,000 viral genomes/cell
resulted in gene targeting frequencies of 0.1 to 0.3% in human
cell lines (24). They have extended these findings to show that
rAAV can mediate gene targeting in a variety of cell types,
with a variety of small mutations, and in a locus-independent
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manner (12–14). While the use of rAAV for creating specific
gene mutations by gene targeting for experimental purposes is
promising (11), the extremely high MOIs required render the
use of rAAV for gene correction for therapeutic purposes less
promising. Not only are such high MOIs practically untenable,
but the random integration of rAAV also has been associated
with genomic rearrangements even at low MOIs (19). The
mechanism by which rAAV mediates gene targeting also re-
mains unclear, and understanding the mechanism may suggest
ways to increase its efficiency.
In this paper, we explore whether the stimulation of gene
targeting by DSBs can be combined with the use of rAAV
vectors. We found that a DSB significantly stimulates rAAV-
induced gene targeting, resulting in high gene targeting fre-
quencies by using lower MOIs. These results suggest that com-
bining AAV with the generation of DSBs is an intriguing
strategy to perform gene targeting and has many characteris-
tics that suggest it may be a powerful way to perform gene
therapy through gene correction.
MATERIALS AND METHODS
DNA manipulations and cloning. Standard molecular biology procedures were
used to make all plasmids (1). rAAV.Subs was made by cloning a 2,700-bp XbaI
fragment from plasmid RS2700 (22) into psub201. rAAV.Subs-Puro was made
replacing the woodchuck posttranscriptional regulatory element of rAAV.Subs
with a puromycin resistance cassette (the puromycin acetyltransferase gene
driven by the simian virus 40 [SV40] promoter). rAAV.Sce was made by placing
the I-SceI (Sce) coding region downstream from the cytomegalovirus enhancer/
chicken -actin promoter into psub201. Plasmid RS2100 and plasmids that ex-
press the Sce endonuclease have been described elsewhere (22). Briefly, RS2100
is a repair substrate that contains the truncated green fluorescent protein (GFP)
gene, internal ribosomal entry site, and CD8 portions but not the woodchuck
posttranscriptional regulatory element of rAAV.Subs in a pBSII (Stratagene, La
Jolla, Calif.) backbone. The Sce expression plasmid consisted of the cytomega-
lovirus promoter driving Sce expression in a pcDNA6 (Invitrogen, Carlsbad,
Calif.) plasmid backbone.
Cell culture and cell lines. 293 cell lines were grown in Dulbecco’s modified
Eagle’s medium (DMEM)–10% calf serum–2 mM L-glutamine–100 U of peni-
cllin/ml–100 g of streptomycin/ml (10% DMEM) in a humidified chamber at
37°C and 5% CO2. Cells were split and passaged by following standard proce-
dures (1). Cell line 293/A658 was made as previously described (22). Briefly, 2
million 293 cells were electroporated with 10 g of linearized plasmid A658, and
G418-resistant colonies were selected by culturing in 500 g of G418 (Invitro-
gen)/ml from day 2 after electroporation until distinct colonies formed (14 days
after electroporation). Individual colonies were picked and grown in 24-well
plates. After the expansion of colonies in 24-well plates, individual colonies were
analyzed for surface CD8 expression with a phycoerythrin-conjugated anti-
CD8 antibody (BD Biosciences, San Diego, Calif.). We used a cell line that
showed high, homogeneous surface expression of CD8.
Transfection of 293 cells. 293 cells were transfected as previously described
(21). Briefly, approximately 100,000 cells were plated in a 24-well plate the day
prior to transfection. Just prior to infection, the medium was changed and, using
a standard calcium phosphate technique (1), 200 ng of Sce expression plasmid
and 200 ng of the repair substrate were cotransfected. Using this procedure, we
routinely obtained transfection efficiencies of 20 to 30%. These efficiencies were
lower than those usually obtained with 293T cells because we were using 293 cells
that had not been SV40 T antigen transformed.
Production and purification of rAAV. rAAV was produced and purified es-
sentially as previously described (10). To produce rAAV, plates of 293T cells
were transfected with three plasmids: pXX2, which supplied the Rep and Cap
proteins of AAV2; pXX6, which contained the adenovirus helper functions; and
a vector plasmid (33). For virus production, five 15-cm-diameter plates were
transfected with 6 g of pXX2, 25 g of pXX6, and 19 g of vector plasmid and
incubated for 72 h. Virus was purified with iodixanol gradients as described
previously (35). Titers of rAAV were determined by real-time PCR with SYBR
Green I double-stranded DNA binding dye and an ABI Prism 7700 sequence
detection system (PE Biosystems, Foster City, Calif.). Samples were prepared as
previously described (8). Throughout this study, MOIs are referred to as the
number of DNase-resistant genomic particles per cell.
Measurement of random integration. The day prior to infection, 50 to 100,000
293-0 or 293/A658 cells were plated in parallel in a 24-well plate and allowed to
adhere overnight in 10% DMEM. Just prior to infection, one well was counted
to determine the number of cells in each well by following standard procedures.
Just prior to infection, the medium in all wells was changed to DMEM–2% fetal
bovine serum–2 mM L-glutamine–100 U of penicillin/ml–100 g of streptomy-
cin/ml (2% DMEM). rAAV.GFP or rAAV.Subs-Puro was then added to the
desired MOI. 24 h after adding virus, the virus containing media was removed
and replaced with 10% DMEM. For rAAV.GFP, at 48 h after infection, each
well was passaged and an aliquot was analyzed by flow cytometry for the per-
centage of GFP-positive cells by a FACScan (settings, FSC E-1 6.06, SSC 350,
FL-1 550, FL-2 550, FL-3 550; compensation, FL2-23.6%-FL-1 and FL3-18.1%-
FL1) (BD Biosciences, San Jose, Calif.). Infected cells were then serially pas-
saged and analyzed by flow cytometry until the percentage of GFP-positive cells
stabilized. To determine the random integration frequency by using antibiotic
resistance, we infected 293/A658 cells with various MOIs of rAAV.Subs-Puro as
described above. Three days after infection, the wells were harvested and 250,000
cells were plated in a 10-cm-diameter plate. At day 4 or day 9 after infection, we
added puromycin to a final concentration of 1 g/ml and grew the cells until
distinct colonies had formed (usually 14 days postinfection). Colonies were
counted by first fixing them in 4% paraformaldehyde, followed by staining with
2% methylene blue in 70% ethanol and washing twice with distilled water. We
found no difference in the number of puromycin-resistant colonies whether we
began antibiotic selection at day 4 or at day 9 after infection. In general, we
interpreted the number of GFP-positive cells at day 14 and the number of
puromycin-resistant colonies as a measurement of the random integration fre-
quency of rAAV in these proliferating 293 cells.
Measurement of gene targeting. Gene targeting frequencies were measured as
followed. The day prior to infection, 293/A658 cells were plated at a density of
approximately 50 to 100,000 cells per well in a 24-well plate. Just prior to
infection, the cell number was determined by counting one well. The medium
was then changed to 2% DMEM, and virus was added to the desired MOI.
Twenty-four hours after infection, the virus-containing medium was replaced
with 10% DMEM. At 48 to 72 h after infection, the cells were split into six-well
plates and allowed to expand. At days 9 to 11 after infection, the percentage of
GFP-positive cells was determined by flow cytometry as described above.
RESULTS
GFP gene targeting system and rAAV vectors. To efficiently
and quantitatively study gene targeting, we developed an assay
based on the correction of a mutated GFP gene that has been
integrated into the genome (Fig. 1A) (22). This assay was
designed to mimic the correction of a small mutation in an
endogenous gene. The mutation in the GFP gene is a 35-bp
insertion consisting of a stop codon followed by the recognition
site for the I-SceI endonuclease (Sce) (an intron-encoded en-
donuclease from Saccharomyces cerevisiae) (15). In this assay,
the frequency of gene targeting is measured by flow cytometry
to quantitate the conversion of GFP-negative cells to GFP-
positive cells. It was previously shown by this system that the
293/A658 cell line is GFP negative, GFP-positive cells are
created only by gene targeting, the frequency of spontaneous
gene targeting following transfection of a double-stranded
DNA plasmid is 7.1  107, and the frequency increases over
2,000-fold when a DSB is introduced at the Sce site in the
targeted GFP gene (22). In this paper, we report the results
with a clonal 293 cell line harboring a single integrated copy of
the GFP target gene but have obtained similar results with
polyclonal cell lines in which the single insertion site of the
target gene is at a variety of different locations. Throughout
this paper, we report the frequencies without normalization to
the efficiency of infection. The frequencies of gene targeting
and random integration are reported as the number of events
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per million cells (a frequency of 10,000, for example, is equiv-
alent to 1%).
To study gene targeting by rAAV with the GFP system, we
generated the rAAV vectors shown schematically in Fig. 1B.
rAAV.Subs and rAAV.Subs-Puro can both serve as repair
substrates in the gene targeting reaction. Both have short,
inactivating 5 truncations in the GFP gene and do not express
GFP. rAAV.Subs has 2,700 bp of homology to the GFP
gene target, and rAAV.Subs-Puro has 2,100 bp of homology.
rAAV.Subs-Puro also contains a puromycin resistance cas-
sette. It can be used to measure both gene targeting through
the measurement of GFP-positive cells and random integra-
tion by counting puromycin-resistant colonies. rAAV.Sce ex-
presses the Sce endonuclease through a strong, ubiquitous
promoter. We used rAAV-GFP to measure the frequencies of
transduction and random integration. rAAV.LacZ has no ho-
mology to the target GFP gene, and we used it to control for
nonspecific effects from rAAV infection. When rAAV.Subs,
rAAV.Subs-Puro, and rAAV.Sce were infected into 293 cells
that do not contain the GFP target gene (293-0 cells), we
detected no GFP-positive cells (less than two per million)
(data not shown). Furthermore, we also did not detect GFP-
positive cells when rAAV.Subs and rAAV.Sce were coinfected
into 293-0 cells (data not shown). Thus, the rAAV repair
substrate and Sce viruses do not recombine to form functional
GFP on their own. As a further control, when rAAV.Sce was
infected into 293/A658 target cells, no GFP-positive cells were
generated because an in-frame stop codon precedes the site of
the Sce-induced DSB and repair of the DSB by nonhomolo-
gous end-joining does not remove this stop codon.
Random integration by using rAAV. We examined the fre-
quency of random integration for rAAV by assessing the random
integration frequency with either rAAV.GFP or rAAV.Subs-
Puro over a range of MOIs (Fig. 2). The kinetics of generating
stably transduced cells was similar at different MOIs, and after
day 14, the number of transduced cells remained stable (Fig.
2A). The percentage of GFP-positive cells remained stable
until at least day 24 after infection (data not shown). The
stability of GFP expression after random integration beyond 24
days was not examined. The frequency of random integration
was dependent on the MOI, and by using an MOI of 10,000,
approximately 1% of the cells were stably GFP positive (Fig.
FIG. 1. Schematics of the GFP gene targeting system components and rAAVs used. (A) Schematic depiction of artificial gene target (A658).
A 35-bp insertion consisting of an in-frame stop codon followed by the recognition site for the Sce endonuclease was inserted at bp 327 of the GFP
coding region. The entire insertion sequence is as follows: 5 TAAGCTCTCGAGATTACCCTGTTATCCCTAAGCTT 3. (B) Schematic
representations of the rAAVs used in this paper. The viruses consist of a single-stranded DNA core with hairpin ends. Repair substrate viruses
rAAV.Subs and rAAV.Subs-Puro are missing the first 36 nucleotides of the GFP coding region. Abbreviations: CMV/CBA, cytomegalovirus
enhancer/chicken -actin promoter; EGFP, enhanced GFP; IRES, internal ribosomal entry site; CD8, coding region for the human CD8 coding
region; WPRE, woodchuck posttranscriptional regulatory element (36); PGK-Neo, neomycin phosphotransferase gene driven by the phospho-
glycerate kinase promoter; TruncGFP, GFP coding region that begins at bp 37 of the coding region; Sce, coding region for the I-SceI endonuclease;
Puro, puromycin acetyltransferase gene driven by the SV40 promoter and containing a polyadenylation signal sequence; CMV, cytomegalovirus
promoter and enhancer; pA, polyadenylation signal sequence; LacZ, coding region for the -galactosidase gene.
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2B). The frequency of random integration was not affected by
the generation of a simultaneous DSB by coinfection of
rAAV.GFP with rAAV.Sce (Fig. 2C). The target gene was
being cleaved after infection with rAAV.Sce because there
were small mutations in the target after rAAV.Sce infection,
consistent with the repair of a DSB by a mutagenic DSB repair
mechanism (data not shown). These mutations were not found
when rAAV.Sce was not infected. We found that the random
integration frequency was 10-fold lower when we used antibi-
otic resistance as a marker rather than GFP expression (com-
pare random integration frequency by using GFP [Fig. 2B]
with random integration frequency by using puromycin resis-
tance [Fig. 2D]), suggesting that GFP is a more sensitive mea-
sure of random integration than antibiotic selection.
Gene targeting using rAAV. To explore whether rAAV
could increase the frequency of spontaneous gene targeting
by the GFP system, we infected 293/A658 target cells with
rAAV.Subs. We found that the frequency of spontaneous gene
targeting increased as the MOI increased (Fig. 3A). The back-
ground frequency of gene targeting with transfected DNA by
this system is 0.71 events/million transfected cells (22); thus, we
found a significant increase only in the frequency of spontane-
ous gene targeting when we used MOIs of 3,000 or greater.
These experiments demonstrated that rAAV can mediate gene
targeting in somatic mammalian cells in a dose-dependent
fashion and confirmed the results of Russell and Hirata (24).
Studies of plasmid-mediated gene targeting suggest that a
DSB in the target gene stimulates gene targeting by activating
the homology-directed repair of the DSB. To examine whether
rAAV-mediated gene targeting can proceed through a similar
mechanism, we measured the frequency of gene targeting by
rAAV in the setting of a DSB (Fig. 3B). We simultaneously
infected 293/A658 cells with rAAV.Subs and transfected a Sce
expression plasmid. We found that at all MOIs of rAAV.Subs,
the transfection of the Sce expression plasmid increased the
frequency of gene targeting. The stimulation was most signif-
icant at low MOIs (stimulation of greater than 60-fold at an
MOI of 300) and reached a plateau at higher MOIs (4-fold
stimulation at an MOI of 10,000). With the transfection of an
Sce expression plasmid, the introduction of the repair substrate
by infection with rAAV did not significantly stimulate gene
targeting more than that by the transfection of supercoiled
plasmid DNA (RS2100) (Fig. 3B).
To investigate whether gene targeting could be stimulated
FIG. 2. Random integration with rAAV. (A) The time course of rAAV transduction is illustrated. This graph shows representative examples
of the time course of transduction of 293 cells with rAAV.GFP at different MOIs. (B) The random integration frequency of rAAV.GFP at various
MOIs is shown. The random integration frequency at each MOI was determined by measuring the percentage of GFP-positive cells by flow
cytometry at day 14 after infection from at least four different infections. (C) The random integration frequency of rAAV.GFP is not affected by
the presence of a DSB. 293/A658 cells were infected with rAAV.GFP  rAAV.Sce at the MOIs indicated, and the percentage of stably transduced
cells was measured by flow cytometry. (D) The random integration frequency with rAAV.Subs-Puro is shown. 293/A658 cells were infected with
rAAV.Subs-Puro at an MOI of either 300 or 1,000, and the numbers of puromycin-resistant colonies were counted at day 21 after infection.
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with only rAAV vectors, we developed a two-virus system by
using coinfection of rAAV.Subs and rAAV.Sce (Fig. 4). We
found that the frequency of gene targeting was directly pro-
portional to the MOI of both viruses (Fig. 4A). Thus, when the
MOI of rAAV.Subs was held constant, the gene targeting
frequency increased as the MOI of rAAV.Sce increased.
Conversely, when the MOI of rAAV.Sce was held constant,
the frequency of gene targeting increased as the MOI of
rAAV.Subs increased. The gene targeting frequency was high-
est (8,000 events/million cells or 0.8%) when we coinfected
rAAV.Subs and rAAV.Sce at an MOI of 10,000 (the highest
MOI tested). Using a combination of allele-specific PCR and
sequencing, we molecularly analyzed GFP-positive cells and
showed that gene targeting had occurred (data not shown).
Substituting rAAV.Subs-Puro for rAAV.Subs as the repair
substrate virus did not change the frequency of gene targeting
(Fig. 4B). The frequency of gene targeting was also not
changed by coinfection with a high MOI of a nonspecific rAAV
(rAAV.LacZ) (Fig. 4C). If the Sce expression cassette and
repair substrate were on the same virus (one-virus system), the
frequency of gene targeting was identical to that by using the
two-virus system (data not shown).
From the measurements of the random integration and gene
targeting frequencies, we calculated the relative frequency of
gene targeting by using rAAV (Table 1). The relative fre-
quency of gene targeting is the ratio of the number of targeted
events compared to the total number of integration events
(targeted events plus random integration events). A higher
relative frequency of gene targeting means that the number of
FIG. 3. Gene targeting with rAAV. (A) The spontaneous fre-
quency of gene targeting with rAAV-Subs is dependent on the MOI.
(B) Transfection of the Sce expression plasmid stimulates rAAV-me-
diated gene targeting. 293/A658 cells were either cotransfected with an
Sce expression plasmid (Sce driven by the PGK promoter) and repair
substrate plasmid (RS2100) or simultaneously transfected with the Sce
expression plasmid and infected with rAAV.Subs. Plasmid RS2100
contains the 2,100-bp repair substrate in rAAV.Subs-Puro, but in the
pBS SK() (Stratagene) backbone (22). The targeting frequencies in
this figure are not adjusted for transfection or infection efficiency.
FIG. 4. DSB-mediated gene targeting can be stimulated by coinfection of rAAV.Sce and rAAV.Subs. (A) Gene targeting frequencies were
obtained after coinfecting different MOIs of rAAV.Subs (along the x axis) and rAAV.Sce (in the figure key). The data for MOIs between 300 and
3,000 are the averages of four to six different samples from two or three different experiments. The data when the MOI was 10,000 for either virus
are the result of one or two samples from a single experiment. (B) rAAV DSB-mediated gene targeting frequency was the same for rAAV.Subs
and rAAV.Subs-Puro. (C) rAAV DSB-mediated gene targeting frequency was not changed by coinfection with a nonspecific rAAV.
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desired targeted events is increased compared to the number
of undesired insertional mutations. The relative frequency of
spontaneous gene targeting with rAAV was significantly better
(1 in 215 at an MOI of 10,000) than that obtained with plasmid
DNA (1 in 14,000) (Table 1). The relative frequency of gene
targeting increased significantly with the introduction of a DSB
because the frequency of gene targeting increased dramatically
and the frequency of random integration did not change. The
relative frequency of gene targeting at an MOI of 10,000 was 1
in 2 (or 50% of all events were targeted) (Table 1). Impor-
tantly, increasing the MOI from 300 to 3,000 increased both
the absolute and relative frequencies of gene targeting. In-
creasing the MOI from 3,000 to 10,000, however, increased the
absolute number of gene targeting events but did not further
increase the relative frequency of gene targeting. While most
cells had undergone either gene targeting or random integra-
tion, there were occasionally cells in which both events oc-
curred (data not shown).
DISCUSSION
Gene correction would be the safest mode of gene therapy
for genetic diseases. It has significant advantages over gene
addition approaches because it does not require knowledge of
the regulatory mechanisms that control gene expression, it
does not suffer from the problem of transgene silencing, and it
does not generate insertional mutations, which are a risk for
any gene addition approach. The problem of insertional mu-
tations has been highlighted by patients developing leukemia
from insertional mutations in the gene therapy trial to treat
X-linked SCID (17). But the low spontaneous frequency of
gene targeting has precluded its use as a therapeutic tool. In
this paper, we describe progress towards solving this problem
by showing that combining rAAV infection with the generation
of DSBs in the target gene can significantly increase both the
absolute and relative frequencies of gene targeting.
rAAV is an efficient, seemingly nonpathogenic virus for the
delivery of DNA to a wide range of cell types (20, 25). Prior
work by Russell and Hirata (24) showed that rAAV could
increase the gene targeting frequency in human somatic cells.
Our results provide the first independent confirmation of their
work. We found that rAAV increased both the absolute and
relative frequencies of spontaneous gene targeting compared
to the transfection of plasmid DNA (Table 1). The absolute
and relative frequencies of spontaneous gene targeting medi-
ated by rAAV are of an order to consider for use in experi-
mental purposes but are still too low to consider for therapeu-
tic purposes.
DNA DSBs in the target gene can stimulate the absolute
gene targeting frequency by several-thousand-fold and con-
comitantly improve the relative frequency of gene targeting by
using plasmid DNA (4, 7, 9, 22, 23, 28, 30, 32). Our work shows
that combining rAAV infection with the introduction of a DSB
also improves both the absolute and relative frequencies of
gene targeting. The stimulation of rAAV gene targeting by a
DSB is evidence that one mechanism of rAAV-mediated gene
targeting is through the homology-directed repair of a DSB.
Thus, rAAV can mediate gene targeting through a mechanism
common to that of naked DNA targeting. Whether rAAV-
mediated spontaneous gene targeting is also initiated by DNA
damage remains to be determined. We found that by coinfect-
ing with rAAVs that contain the repair substrate and an Sce
expression cassette, we could obtain an absolute gene targeting
frequency of 8,000 per million cells (0.8%) and a relative fre-
quency of 1 in 2. The use of a rAAV that expresses Sce thus
stimulated the absolute and relative frequency of gene target-
ing by 100- to 300-fold. In comparison with that determined by
Russell and Hirata (24), the combined use of rAAV.Subs and
rAAV.Sce increased the frequency of gene targeting by 4- to
8-fold while using 40-fold less virus. Using lower MOIs to
achieve the same or greater gene targeting frequencies has
several advantages. First, it makes the use of rAAV to mediate
gene targeting practically tenable. Second, it increases the
safety of using rAAV. Miller et al. showed that infection with
rAAV is associated with genomic rearrangements (19).
Whether rAAV is an active part of creating the rearrange-
ments or just a passive marker remains to be determined.
Moreover, we have demonstrated that the number of inser-
tional mutations (another form of genomic instability) is di-
rectly related to the MOI of rAAV. Thus, being able to use
lower MOIs makes rAAV significantly safer to use.
Using the two-virus system, we found that the frequency of
gene targeting was dependent on the amounts of both Sce virus
and substrate virus. When, for example, the amount of Sce
virus was held constant, the targeting frequency increased dra-
matically as the amount of substrate virus was increased. Con-
versely, when the amount of substrate virus was held constant,
the targeting frequency increased dramatically as the amount
of Sce virus was increased. Thus, by increasing the number of
DSBs, the frequency of gene targeting for a given MOI of
TABLE 1. Random integration and gene targeting frequencies with rAAV
DNA Random integrationfrequencya (GFP)
Gene targeting frequency
n-Fold stimulation
by Sce
Relative gene targeting
frequency (substrate  Sce)Absolutea
(substrate) Relative (substrate)
Absolutea
(substrate
 Sce)
Plasmid 10,000 0.71 7.1  105 (1/14,000) 1,600 2,200 1.4  101 (1/7)
MOI of rAAV
300 1,000 	2 	2  103 (	1/500) 15 
7 1.5  102 (1/68)
1,000 2,300 3 1.3  103 (1/750) 393 130 1.5  101 (1/7)
3,000 3,300 10 2.9  103 (1/340) 3180 320 4.9  101 (1/2)
10,000 10,100 47 4.6  103 (1/215) 8,070 170 4.4  101 (1/2)
a Value given is per million cells.
VOL. 23, 2003 GENE TARGETING BY AAV 3563
substrate virus increased dramatically. The dual dependence
on substrate virus and Sce virus suggests that both the repair
substrate and the DSB were limiting in the targeting reaction.
Overall, the results we obtained are in agreement and comple-
ment the results obtained by D. Miller et al. (18a). Despite
using different markers as target genes, different cell lines, and
different ways to introduce the Sce endonuclease, we both
found that the frequency of rAAV-mediated gene targeting
was increased significantly by the introduction of a DSB and
that the mechanism of rAAV-mediated gene targeting can
proceed through the homology-directed repair of a DSB.
Although the frequency of spontaneous gene targeting with
rAAV is superior to that with plasmids, we found that the
frequencies of DSB-mediated gene targeting are similar. We
obtained gene targeting frequencies of 1% when transfecting
plasmid DNA (which increases to 3 to 5% when we normalize
for transfection efficiency), which is of the same magnitude of
0.8% that we obtained by using rAAV (22). The use of rAAV
to introduce both components necessary for gene targeting (a
repair substrate and an endonuclease to create a DSB) repre-
sents a major advance because it significantly broadens the
range of cell types that can be considered for gene targeting.
The data of Miller et al. (18a) provide direct evidence that
rAAV and DSBs can be used to stimulate gene targeting in
primary cells.
While an absolute gene targeting frequency of 0.8% and a
relative frequency of 50% approach levels of therapeutic utility
and safety, important problems remain. The first problem is to
develop methods to create sequence-specific breaks at any site
in the genome in a safe and efficient manner. Chimeric nucle-
ases, fusions between a zinc finger DNA binding domain and
an endonuclease domain, have been shown to cleave extra-
chromosomal DNA in Xenopus oocytes and genomic DNA in
Drosophila melanogaster (2, 3, 6). It was recently shown that
chimeric nucleases can stimulate gene targeting in human so-
matic cells by several-thousand-fold (22). Performing gene tar-
geting by designing chimeric nucleases to stimulate gene tar-
geting at any gene and by using rAAV to introduce the
nucleases is an experimental approach that should be investi-
gated and has a strong probability of working. The second
problem is to understand further the parameters of rAAV that
make it an efficient substrate for gene targeting. Our data
suggest that a mechanism of rAAV-mediated gene targeting,
as for other forms of gene targeting, is through the repair of
DNA DSBs. It was previously shown that the frequency of
DSB-mediated gene targeting by using plasmid DNA is depen-
dent on the amount of repair substrate introduced (22). The
dose response of gene targeting with rAAV suggests that mass
action effects, i.e., simply the ability of rAAV to bring DNA
efficiently into cells, are an important aspect of the mechanism
of rAAV-mediated gene targeting. But other features, includ-
ing the possibilities that the single-stranded DNA structure of
rAAV is preferred by the gene targeting machinery and that
rAAV infection activates the machinery of gene targeting may
also contribute. The third problem is to further reduce the
number of random insertions. While a relative frequency of
gene targeting of 1 in 2 is excellent, it still means that for each
targeted event, there is an insertional mutation. In fact, occa-
sionally both events can occur in the same cell. It may be
possible to shift the balance of integration events further to-
wards targeted events and away from random events and thus
continue to reduce the risk of insertional mutagenesis. None-
theless, we believe that our study and those of others support
the promise of AAV as a vector for gene correction type gene
therapy, particularly for genetic diseases that result from small
mutations.
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